Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development
Dr Korsgren to lead the research and development of Hansa’s proprietary enzyme technology platform as the Company expands also into new therapeutic areasLund, Sweden March 1, 2021. Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces the appointment of Magnus Korsgren, M.D., Ph.D. as Vice President and Head of Research and Development. Dr Korsgren will lead the efforts to advance Hansa Biopharma’s pipeline of drug candidates for rare immunologic diseases based on the Company’s proprietary IgG-cleaving enzyme technology